Initial interim 52-week results from Phase 2b Population Extension cohort of PRISM clinical trial to be presented by Dante Pieramici, M.D., a Principal Investigator in PRISM, at Angiogenesis ...

Detailed price information for 4D Molecular Therapeutics Inc (FDMT-Q) from The Globe and Mail including charting and trades.

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic ...

Inhibrx, Inc. logo (PRNewsfoto/Inhibrx ... cohort to validate these findings in a more uniform patient population. The cohort is expected to enroll up to 50 patients, each with two to three ...

AI-Guided Cardiac Ablation in combination with pulmonary vein isolation was superior to the standard of care in the treatment of Persistent ...

Research reveals that even low levels of air pollution significantly increase the risk of respiratory infections in adults, ...

The study reveals SGLT-2is are linked to fewer COPD exacerbations in type 2 diabetes, suggesting a need for further clinical ...

Generation Beta officially starts this year. Researchers have already predicted the world they will come of age in.

PK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial results BOSTON, Feb. 6, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company ...

The dose administered to patients in the third cohort is approximately double the dose administered in the second cohort. Logo (PRNewsfoto/TransCode Therapeutics, Inc.) Several patients in the first ...